Cargando…
Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co-inhibitory signaling of Programmed Cell Death Ligand-1 (PD-L1) and its receptor Programmed Cell Death-1 (PD-1). The combined eval...
Autores principales: | Keber, Corinna U., Derigs, Marcus, Schultz, Carolin, Wegner, Moritz, Lingelbach, Susanne, Wischmann, Viktoria, Hofmann, Rainer, Denkert, Carsten, Hegele, Axel, Hänze, Jörg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463294/ https://www.ncbi.nlm.nih.gov/pubmed/35184226 http://dx.doi.org/10.1007/s00262-022-03166-9 |
Ejemplares similares
-
Soluble PD-L1 in blood correlates positively with neutrophil and negatively with lymphocyte mRNA markers and implies adverse sepsis outcome
por: Derigs, Marcus, et al.
Publicado: (2022) -
Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer
por: Hänze, Jörg, et al.
Publicado: (2020) -
Modulation of immune checkpoint regulators in interferon γ induced urothelial carcinoma and activated T-lymphocyte cells by cytostatics
por: Hänze, Jörg, et al.
Publicado: (2023) -
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021) -
Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?
por: Hegele, Axel, et al.
Publicado: (2014)